We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other best and worst dow stocks for the next 12 months. The Dow Jones …

We recently published a list of 11 Worst-Performing Blue Chip Stocks So Far in 2025. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other worst-performing blue chip stocks so far in 2025. Blue chip …

We recently published a list of Billionaire Cliff Asness’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other billionaire Cliff Asness’ stock picks with huge …

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most profitable blue chip stocks to buy now. Blue chip stocks are …

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Billionaire Ken Fisher’s …

Our stock screening tool has identified MERCK & CO. INC. (NYSE:MRK) as an undervalued gem with strong fundamentals. MRK boasts decent financial health and profitability while maintaining an attractive price point. We'll break it down further. What …

… Laboratories, Inc., Janssen Pharmaceuticals, Inc., Merck and Co., Inc., Novartis, among others. Bipolar …

Moderna Inc. shares declined after the company’s first-quarter vaccine sales missed estimates and it disclosed a delay in the US regulatory review of a combination flu and COVID shot. For a company burning cash and missing sales projections, “it’s very …

The basics: Novartis plans to acquire clinical stage biotech Regulus Therapeutics in a deal worth up to $1.7 billion. Under the terms announced April 30, the Swiss drugmaker will make an upfront payment of $800 million to the San Diego-based company. If …

Today, a brief rundown of news involving Arvinas and Biogen, as well as updates from Merck & Co., Entrada Therapeutics and Valneva that you may have missed. Arvinas will lay off about a third of its workforce and scrap a pair of anticipated Phase 3 …